KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis

Company Overview

KalVista Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of small-molecule protease inhibitors. The company’s research centers on plasma kallikrein and other serine proteases implicated in a range of diseases, including hereditary angioedema (HAE), diabetic macular edema (DME) and other protease‐mediated disorders. KalVista leverages proprietary chemistry and biology platforms to generate orally administered inhibitors with the potential to address unmet medical needs.

The company’s lead programs target both on-demand and prophylactic treatment of HAE through selective plasma kallikrein inhibitors. KVD900 is being evaluated for acute attack management, while KVD824 is designed for long‐term prophylaxis. In ophthalmology, KVD001 is under development as an intravitreal therapy for DME, having demonstrated proof‐of‐concept in early clinical studies. Additional preclinical programs extend KalVista’s reach into other protease‐driven conditions, reinforcing its strategy of using a singular modality across multiple therapeutic areas.

Headquartered in Cambridge, United Kingdom, with a complementary research and development site in Cambridge, Massachusetts, KalVista maintains operations that span Europe and North America. The company has established collaborations with academic institutions and contract research organizations to support its discovery efforts and clinical development programs. These partnerships enhance KalVista’s capabilities in translational science and regulatory strategy.

Originally founded in 2006 as a protease inhibitor research unit within Vernalis plc, KalVista was spun out in 2015 to focus exclusively on small-molecule therapies. The company is led by President and Chief Executive Officer Cal Alvarez, whose leadership team brings extensive expertise in pharmaceutical development, regulatory affairs and commercial planning. KalVista remains committed to advancing its pipeline through clinical milestones and fostering strategic alliances to deliver innovative treatments for patients.

Key Stats

• Today's Range: $13.85 to $15.00
• 50-Day Range: $11.22 to $15.99
• 52-Week Range: $7.30 to $16.32
• Volume: 2.09 million shs
• Average Volume: 572,060 shs
• Market Capitalization: $721.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.29
• Consensus Rating: Buy

KalVista Pharmaceuticals Stock Analysis - MarketRank™

KalVista Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 199th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

KalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

KalVista Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.56) to ($2.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of KalVista Pharmaceuticals is -3.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of KalVista Pharmaceuticals is -3.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

KalVista Pharmaceuticals has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.10% of the float of KalVista Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

KalVista Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in KalVista Pharmaceuticals has recently increased by 36.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

KalVista Pharmaceuticals does not currently pay a dividend.

Dividend Growth

KalVista Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.18

Percentage of Shares Shorted

19.10% of the float of KalVista Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

KalVista Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in KalVista Pharmaceuticals has recently increased by 36.00%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.70

News Sentiment

KalVista Pharmaceuticals has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 43 news articles for KalVista Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

12 people have searched for KALV on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

4 people have added KalVista Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, KalVista Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $723,617.00 in company stock.

Percentage Held by Insiders

10.50% of the stock of KalVista Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

KALV Stock Analysis - Frequently Asked Questions

How have KALV shares performed this year?

KalVista Pharmaceuticals' stock was trading at $8.47 on January 1st, 2025. Since then, KALV shares have increased by 71.4% and is now trading at $14.52.

How were KalVista Pharmaceuticals' earnings last quarter?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) issued its earnings results on Thursday, July, 10th. The specialty pharmaceutical company reported ($3.69) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by $2.86.

How do I buy shares of KalVista Pharmaceuticals?

Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of KalVista Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that KalVista Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Chevron (CVX) and Netflix (NFLX).

Company Calendar

• Last Earnings: 7/10/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 9/04/2025
• Fiscal Year End: 4/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KALV
• CIK: 1348911
• Web: www.kalvista.com
• Phone: 857-999-0075
• Fax: 866-553-3269
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for KalVista Pharmaceuticals: $26.29
• High Price Target: $30.00
• Low Price Target: $20.00
• Potential Upside/Downside: +81.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$126.64 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -121.78%
• Return on Assets: -86.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.44
• Quick Ratio: 10.44

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.86 per share
• Price / Book: 2.99

Miscellaneous

• Outstanding Shares: 49,720,000
• Free Float: 44,496,000
• Market Cap: $721.93 million
• Optionable: Optionable
• Beta: -0.04